Impact of Oral Protein on Nutritional Status and Quality of Life in HD Patients

Sponsor
Alexandria University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05952570
Collaborator
(none)
100
1
2
4.5
22.4

Study Details

Study Description

Brief Summary

The aim of this work is to study the effects of oral protein-based supplements on nutritional status in hemodialysis patients

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: oral protein nutritional supplement (Fresubin protein powder)
  • Other: routine nutrition regimen
N/A

Detailed Description

Chronic kidney disease (CKD) is a prevalent chronic condition and the incidence of end-stage renal disease (ESRD) is expected to increase over the next few decades. In patients with CKD, especially in those with ESRD and undergoing maintenance dialysis therapy (MDT), a state of metabolic and nutritional derangements, more aptly called protein-energy wasting (PEW), caused by a combination of insufficient intake, uremic toxins, inflammation, and superimposed catabolism, plays a major role among the many risk factors that affect outcomes of CKD .

Oral nutritional supplement (ONS) is a simple and effective way to supplement energy and protein to malnourished patients on the basis of regular diet. Therefore, if the protein of regular diet in dialysis patients are not enough, they should be supplemented with (ONS) when appropriate.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This research is a randomized multi-center clinical trial in which 100 hemodialysis patients will be randomly assigned to one of the study groups using block randomization with a ratio of 1:1. Group A: 50 patients will receive oral protein nutritional supplement (Fresubin protein powder 25mg/5scoops per hemodialysis session) for 3 months. Group B: 50 patients will receive a routine nutrition regimen for 3 months. (control group)This research is a randomized multi-center clinical trial in which 100 hemodialysis patients will be randomly assigned to one of the study groups using block randomization with a ratio of 1:1. Group A: 50 patients will receive oral protein nutritional supplement (Fresubin protein powder 25mg/5scoops per hemodialysis session) for 3 months. Group B: 50 patients will receive a routine nutrition regimen for 3 months. (control group)
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Impact of Oral Protein-based Supplements on Nutritional Status and Quality of Life in Hemodialysis Patients
Anticipated Study Start Date :
Aug 1, 2023
Anticipated Primary Completion Date :
Oct 15, 2023
Anticipated Study Completion Date :
Dec 15, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: protein supplement

50 patients will receive oral protein nutritional supplement (Fresubin protein powder 25mg/5scoops per hemodialysis session) for 3 months

Dietary Supplement: oral protein nutritional supplement (Fresubin protein powder)
50 patients will receive oral protein nutritional supplement (Fresubin protein powder 25mg/5scoops per hemodialysis session) for 3 months

Placebo Comparator: control

50 patients will receive a routine nutrition regimen for 3 months. (control group)

Other: routine nutrition regimen
50 patients will receive a routine nutrition regimen for 3 months. (control group)

Outcome Measures

Primary Outcome Measures

  1. effect on nutritional status [3 months]

    assessment of nutritional status change at 3 months from baseline using Subjective Global Assessment (SGA)

  2. effect on quality of life [3 months]

    assessment of quality of life change at 3 months from baseline using the kidney disease quality of life 36 (KDQOL-36) short form

Secondary Outcome Measures

  1. effect on BMI [3 months]

    BMI assessment change at 3 months from baseline

  2. mid arm circumference and triceps skin fold [3 months]

    Measurement of mid arm circumference and triceps skin fold change at 3 months from baseline

  3. dialysis adequacy [3 months]

    Estimation of Kt/V change at 3 months from baseline

  4. effect on serum albumin [3 months]

    measurement of serum albumin change at 3 months from baseline

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult hemodialysis patients (≥18 years of age).

  • Received dialysis for at least 6 months prior to study screening.

  • Receive hemodialysis at least 3 times per week .

Exclusion Criteria:
  • Receiving nutritional supplementation prior to study commencing or within 1 month of commencement in the study .

  • Participants with an allergy to any ingredients in the nutritional supplements.

  • Persistent hyperkalemia or hyperphosphatemia (defined as the last 3 months).

  • Significant edema and fluid overload.

  • Hepatic patients

Contacts and Locations

Locations

Site City State Country Postal Code
1 Faculty of Medicine, Aexandria University Alexandria Egypt 21526

Sponsors and Collaborators

  • Alexandria University

Investigators

  • Study Chair: Mohamed Mamdouh Elsayed, MD, lecturer
  • Study Chair: Amr El Kazaz, MBBCh, resident
  • Study Chair: Eman E EL Gohary, MD, Professor
  • Principal Investigator: Mohamed M Abdel Kader, MD, Professor

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Mohamed Mamdouh Mahmoud Mohamed Elsayed , MD, Lecturer, Alexandria University
ClinicalTrials.gov Identifier:
NCT05952570
Other Study ID Numbers:
  • oral protein in HD
First Posted:
Jul 19, 2023
Last Update Posted:
Jul 19, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Mohamed Mamdouh Mahmoud Mohamed Elsayed , MD, Lecturer, Alexandria University

Study Results

No Results Posted as of Jul 19, 2023